Announcement PDF ASX Announcement Results of 2023 Annual General Meeting SYDNEY Australia, 8 November 2023: Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), provides the following information in relation to the resolutions put to the shareholders of the Company at its Annual General Meeting held today at 9:00am (AEDT). All resolutions were decided by way of poll and were passed with the exception of Resolution 1 which was not passed. As more than 25% of the votes cast on Resolution 1 were against the adoption of the 2023 Remuneration Report, this constitutes a ‘first strike’ for purposes of the Corporations Act 2001 (Cth). In accordance with ASX Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), a summary of the proxy votes and the number of votes cast on each resolution in the poll is attached. This announcement has been approved for release by Recce Pharmaceuticals Board. About Recce Pharmaceuticals Ltd Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date. The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world’s only synthetic polymer and sepsis drug candidate in development. RECCE® 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy. Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs. Disclosure of Proxy Votes Automic GPO Box 5193, Sydney, NSW 2001 P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world) F +61 (0)2 8583 3040 E hello@automic.com.au ABN 27 152 260 814 Recce Pharmaceuticals Ltd Annual General Meeting Wednesday, 08 November 2023 In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting. Poll Results (if applicable) Proxy Votes Resolution Decided by Show of Hands (S) or Poll (P) Total Number of Proxy Votes exercisable by proxies validly appointed 1 Adoption of Remuneration Report P 34,929,009 2 Re-election of Michele Dilizia as Director P 38,681,493 3 Re-election of Dr Justin Ward as Director P 38,403,893 4 ASX Listing Rule 7.1A Approval of Future Issue of Securities P 38,672,680 5 Ratification of Prior Issue of Placement Shares P 25,911,655 6 Adoption of Employee Incentive Plan P 30,231,399 7 Approval of Issue of Shortfall Shares to Dr John Prendergast, Director of the Company P 38,548,663 8 Approval of Issue of Shortfall Shares to Dr Alan Dunton, Director of the Company P 38,548,663 FOR AGAINST 8,934,368 21,733,319 25.58% 62.22% 34,255,430 176,741 88.56% 0.46% 21,410,205 12,744,366 55.75% 33.19% 33,952,574 456,139 87.79% 1.18% 21,325,691 331,997 82.30% 1.28% 16,940,400 8,835,111 56.04% 29.22% 33,998,828 300,015 88.20% 0.78% 34,036,828 262,015 88.30% 0.68% ABSTAIN 67,093 25,472 303,072 34,285 12,793,012 3,635,486 158,302 158,302 PROXY'S DISCRETION FOR AGAINST 4,261,322 15,534,752 21,772,862 12.20% 41.64% 58.36% 4,249,322 41,209,318 176,741 10.99% 99.57% 0.43% 4,249,322 28,364,093 12,754,366 11.06% 68.98% 31.02% 4,263,967 40,861,564 505,682 11.03% 98.78% 1.22% 4,253,967 28,254,681 371,540 16.42% 98.70% 1.30% 4,455,888 23,692,040 8,884,654 14.74% 72.73% 27.27% 4,249,820 40,673,671 339,558 11.02% 99.17% 0.83% 4,249,820 40,901,671 301,558 11.02% 99.27% 0.73% Results ABSTAIN OUTCOME 67,093 - 35,472 Passed 303,072 Passed 54,285 Passed 12,793,012 Passed 3,655,486 Passed 158,302 Passed 158,302 Passed Poll Results (if applicable) Proxy Votes Resolution 9 Approval of Issue of Shortfall Shares to Dr Justin Ward, Director of the Company Decided by Show of Hands (S) or Poll (P) P Total Number of Proxy Votes exercisable by proxies validly appointed 38,383,583 FOR AGAINST 33,836,748 297,015 88.15% 0.77% ABSTAIN 323,382 PROXY'S DISCRETION FOR AGAINST 4,249,820 40,761,591 336,558 11.07% 99.18% 0.82% Results ABSTAIN 323,382 OUTCOME Passed